Late-onset right ventricular dysfunction after mechanical support by a continuous-flow left ventricular assist device

BACKGROUND: Right heart failure (RHF) is a serious post-operative complication of left ventricular assist device (LVAD) implantation, with significant morbidity and mortality. Many clinical, hemodynamic and laboratory variables have been shown to have prognostic value for appearance of RHF. We sought to investigate the incidence of new-onset right ventricular dysfunction (RVD) complicating the long-term use of LVADs. METHODS: We retrospectively examined all patients supported with a continuous-flow LVAD for >1 year at our center. RESULTS: Twenty patients (mean age 54 +/- 10 years, 95% men, 60% with ischemic cardiomyopathy, left ventricular ejection fraction 22 +/- 6%, pulmonary capillary wedge pressure 23.5 +/- 7.5 mm Hg, brain natriuretic peptide [BNP] 1,566 1,536 pg/ml, serum creatinine 1.6 +/- 0.64 mg/di, furosemide dose 643 +/- 410 mg/day) underwent long-term mechanical support as destination therapy support with a continuous-flow LVAD (HeartMate IQ at our center. During follow-up (1,219 +/- 692 days), 9 patients (45%) manifested symptoms and signs of RVD (increase in right atrial pressure [RAP], BNP and daily furosemide dose compared with the early post-operative period). In these patients, RAP was increased by 6.6 +/- 2.6 mm Hg and BNP by 526 +/- 477 pg/ml, whereas furosemide dose increased by 145 +/- 119 mg. The mean and median times of RVD onset were 2.3 +/- 1.5 and 2.1 years, respectively, after LVAD implantation (range 0.4 to 4.8 years). Four of these patients (44.4%) demonstrated further deterioration of RV function and died 73 +/- 106 days (median 25 days, range 9 to 231 days) after first manifestation of RVD. Comparisons of baseline variables regarding medical history and clinical status did not demonstrate significant differences between the patients with or without RVD, including parameters related to RV function at the time of implantation. CONCLUSIONS: Late-onset RVD is a complication of LVAD support, which can manifest several months to years from device implantation. This complication has significant adverse implications with regard to patient outcome. Prognostic factors need to be identified to follow and treat high-risk patients more efficiently. (C) 2015 International Society for Heart and Lung Transplantation. All rights reserved.